{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T10:20:06Z","timestamp":1794997206398,"version":"4.9.1"},"reference-count":51,"publisher":"American Association for Cancer Research (AACR)","issue":"5","license":[{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013873","name":"Government of Ontario","doi-asserted-by":"crossref","award":["OICR-TRI-Ovarian"],"award-info":[{"award-number":["OICR-TRI-Ovarian"]}],"id":[{"id":"10.13039\/100013873","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5,4]]},"abstract":"<jats:p>Drug repurposing is an attractive option for oncology drug development. Itraconazole is an antifungal ergosterol synthesis inhibitor that has pleiotropic actions including cholesterol antagonism, inhibition of Hedgehog and mTOR pathways. We tested a panel of 28 epithelial ovarian cancer (EOC) cell lines with itraconazole to define its spectrum of activity. To identify synthetic lethality in combination with itraconazole, a whole-genome drop-out genome-scale clustered regularly interspaced short palindromic repeats sensitivity screen in two cell lines (TOV1946 and OVCAR5) was performed. On this basis, we conducted a phase I dose-escalation study assessing the combination of itraconazole and hydroxychloroquine in patients with platinum refractory EOC (NCT03081702). We identified a wide spectrum of sensitivity to itraconazole across the EOC cell lines. Pathway analysis showed significant involvement of lysosomal compartments, the trans-golgi network and late endosomes\/lysosomes; similar pathways are phenocopied by the autophagy inhibitor, chloroquine. We then demonstrated that the combination of itraconazole and chloroquine displayed Bliss defined synergy in EOC cancer cell lines. Furthermore, there was an association of cytotoxic synergy with the ability to induce functional lysosome dysfunction, by chloroquine. Within the clinical trial, 11 patients received at least one cycle of itraconazole and hydroxychloroquine. Treatment was safe and feasible with the recommended phase II dose of 300 and 600 mg twice daily, respectively. No objective responses were detected. Pharmacodynamic measurements on serial biopsies demonstrated limited pharmacodynamic impact. In vitro, itraconazole and chloroquine have synergistic activity and exert a potent antitumor effect by affecting lysosomal function. The drug combination had no clinical antitumor activity in dose escalation.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>The combination of the antifungal drug itraconazole with antimalarial drug hydroxychloroquine leads to a cytotoxic lysosomal dysfunction, supporting the rational for further research on lysosomal targeting in ovarian cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-22-0037","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T11:48:57Z","timestamp":1650887337000},"page":"293-306","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer"],"prefix":"10.1158","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1423-613X","authenticated-orcid":true,"given":"Stefano","family":"Marastoni","sequence":"first","affiliation":[{"name":"1Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7166-9762","authenticated-orcid":true,"given":"Ainhoa","family":"Madariaga","sequence":"additional","affiliation":[{"name":"2Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada."},{"name":"3Autonomous University of Barcelona, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1394-4417","authenticated-orcid":true,"given":"Aleksandra","family":"Pesic","sequence":"additional","affiliation":[{"name":"1Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sree Narayanan","family":"Nair","sequence":"additional","affiliation":[{"name":"1Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu Juan","family":"Li","sequence":"additional","affiliation":[{"name":"1Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zvi","family":"Shalev","sequence":"additional","affiliation":[{"name":"1Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy","family":"Ketela","sequence":"additional","affiliation":[{"name":"1Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0602-8667","authenticated-orcid":true,"given":"Ilaria","family":"Colombo","sequence":"additional","affiliation":[{"name":"2Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Mandilaras","sequence":"additional","affiliation":[{"name":"2Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cabanero","sequence":"additional","affiliation":[{"name":"4Department of Pathology, Toronto General Hospital, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5509-9990","authenticated-orcid":true,"given":"Jeff P.","family":"Bruce","sequence":"additional","affiliation":[{"name":"1Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Li","sequence":"additional","affiliation":[{"name":"2Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Garg","sequence":"additional","affiliation":[{"name":"2Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Wang","sequence":"additional","affiliation":[{"name":"2Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4581-8848","authenticated-orcid":true,"given":"Eric X.","family":"Chen","sequence":"additional","affiliation":[{"name":"2Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarbjot","family":"Gill","sequence":"additional","affiliation":[{"name":"2Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neesha C.","family":"Dhani","sequence":"additional","affiliation":[{"name":"2Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"2Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melania","family":"Pintilie","sequence":"additional","affiliation":[{"name":"5Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Bowering","sequence":"additional","affiliation":[{"name":"2Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0547-2480","authenticated-orcid":true,"given":"Marianne","family":"Koritzinsky","sequence":"additional","affiliation":[{"name":"1Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada."},{"name":"6Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada."},{"name":"7Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada."},{"name":"8Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Rottapel","sequence":"additional","affiliation":[{"name":"1Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8187-592X","authenticated-orcid":true,"given":"Bradly G.","family":"Wouters","sequence":"additional","affiliation":[{"name":"1Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada."},{"name":"7Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada."},{"name":"8Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9510-8641","authenticated-orcid":true,"given":"Amit M.","family":"Oza","sequence":"additional","affiliation":[{"name":"2Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5159-4580","authenticated-orcid":true,"given":"Anthony M.","family":"Joshua","sequence":"additional","affiliation":[{"name":"1Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada."},{"name":"9Kinghorn Cancer Centre, Department of Medical Oncology, St Vincents Hospital, Sydney, Australia."},{"name":"10Garvan Institute of Medical Research, Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Lheureux","sequence":"additional","affiliation":[{"name":"2Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2022,5,4]]},"reference":[{"key":"2023030220225236900_","article-title":"SEER Cancer Statistics Review, 1975\u20132015, NCI, Bethesda, MD","author":"Noone","year":"2018"},{"key":"2023030220225236900_","first-page":"166","article-title":"Morphologic, immunophenotypic, and molecular features of epithelial ovarian cancer","volume":"30","author":"Ramalingam","year":"2016","journal-title":"Oncology"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3322\/caac.21559","article-title":"Epithelial ovarian cancer: Evolution of management in the era of precision medicine","volume":"69","author":"Lheureux","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2020.08.013","article-title":"New approaches for targeting platinum-resistant ovarian cancer","volume":"77","author":"Mcmullen","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3332\/ecancer.2015.521","article-title":"Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent","volume":"9","author":"Pantziarka","year":"2015","journal-title":"Ecancermedicalscience"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1634\/theoncologist.2012-314","article-title":"Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer","volume":"18","author":"Antonarakis","year":"2013","journal-title":"Oncologist"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3892\/ol.2017.6325","article-title":"Repurposing itraconazole as an anticancer agent","volume":"14","author":"Tsubamoto","year":"2017","journal-title":"Oncol Lett"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"6764","DOI":"10.1158\/0008-5472.CAN-11-0691","article-title":"Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer","volume":"71","author":"Aftab","year":"2011","journal-title":"Cancer Res"},{"key":"2023030220225236900_","first-page":"27","article-title":"Itraconazole can inhibit malignant pleural effusion by suppressing lymphangiogenesis in mice","volume":"4","author":"Wang","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"28510","DOI":"10.18632\/oncotarget.15324","article-title":"Itraconazole exerts its anti-melanoma effect by suppressing Hedgehog, Wnt, and PI3K\/mTOR signaling pathways","volume":"8","author":"Liang","year":"2017","journal-title":"Oncotarget"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ccr.2012.11.017","article-title":"Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists","volume":"23","author":"Kim","year":"2013","journal-title":"Cancer Cell"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"E7276","DOI":"10.1073\/pnas.1512867112","article-title":"Antifungal drug itraconazole targets VDAC1 to modulate the AMPK\/mTOR signaling axis in endothelial cells","volume":"112","author":"Head","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1073\/pnas.0910872107","article-title":"Cholesterol trafficking is required for mTOR activation in endothelial cells","volume":"107","author":"Xu","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1021\/acschembio.6b00849","article-title":"Simultaneous targeting of NPC1 and VDAC1 by itraconazole leads to synergistic inhibition of mTOR signaling and angiogenesis","volume":"12","author":"Head","year":"2017","journal-title":"ACS Chem Biol"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1200\/JCO.2013.49.9525","article-title":"Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma","volume":"32","author":"Kim","year":"2014","journal-title":"J Clin Oncol"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/JTO.0b013e31828c3950","article-title":"Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer","volume":"8","author":"Rudin","year":"2013","journal-title":"J Thorac Oncol"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/pcan.2015.42","article-title":"Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science","volume":"19","author":"Nussbaum","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2023030220225236900_","first-page":"2481","article-title":"Impact of combination chemotherapy with itraconazole on survival of patients with refractory ovarian cancer","volume":"34","author":"Tsubamoto","year":"2014","journal-title":"Anticancer Res"},{"key":"2023030220225236900_","first-page":"2007","article-title":"Impact of combination chemotherapy with itraconazole on survival for patients with recurrent or persistent ovarian clear cell carcinoma","volume":"34","author":"Tsubamoto","year":"2014","journal-title":"Anticancer Res"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13073-019-0665-3","article-title":"Identifying chemogenetic interactions from CRISPR screens with drugZ","volume":"11","author":"Colic","year":"2019","journal-title":"Genome Med"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"a016840","DOI":"10.1101\/cshperspect.a016840","article-title":"The biogenesis of lysosomes and lysosome-related organelles","volume":"6","author":"Luzio","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/978-1-4939-6934-0_19","article-title":"Lysosomal biology in cancer","volume":"1594","author":"Fennelly","year":"2017","journal-title":"Methods Mol Biol"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/nyas.12953","article-title":"Targeting the lysosome in cancer","volume":"1371","author":"Piao","year":"2016","journal-title":"Ann N Y Acad Sci"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41580-019-0185-4","article-title":"Lysosomes as dynamic regulators of cell and organismal homeostasis","volume":"21","author":"Ballabio","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2023030220225236900_","first-page":"9104","article-title":"High expression of LAMP1 as a prognostic marker in patients with epithelial ovarian cancer","volume":"10","author":"Xu","year":"2017","journal-title":"Int J Clin Exp Pathol"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/s41573-019-0036-1","article-title":"Lysosomes as a therapeutic target","volume":"18","author":"Bonam","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3332\/ecancer.2017.781","article-title":"Repurposing Drugs in Oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents","volume":"11","author":"Verbaanderd","year":"2017","journal-title":"Ecancermedicalscience"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1016\/j.celrep.2017.02.028","article-title":"Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer","volume":"18","author":"Medrano","year":"2017","journal-title":"Cell Rep"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.cell.2015.11.015","article-title":"High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities","volume":"163","author":"Hart","year":"2015","journal-title":"Cell"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"10787","DOI":"10.1073\/pnas.191368598","article-title":"Chemosensitivity prediction by transcriptional profiling","volume":"98","author":"Staunton","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1186\/s12885-015-1492-6","article-title":"Anticancer drug sensitivity prediction in cell lines from baseline gene expression through recursive feature selection","volume":"15","author":"Dong","year":"2015","journal-title":"BMC Cancer"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"D419","DOI":"10.1093\/nar\/gkw1082","article-title":"pathDIP: an annotated resource for known and predicted human gene-pathway associations and pathway enrichment analysis","volume":"45","author":"Rahmati","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","article-title":"SynergyFinder 2.0: visual analytics of multi-drug combination synergies","volume":"48","author":"Ianevski","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2165\/00003495-199651040-00006","article-title":"Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections","volume":"51","author":"Haria","year":"1996","journal-title":"Drugs"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/art.39402","article-title":"Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus","volume":"68","author":"Lee","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2023030220225236900_","first-page":"145","article-title":"Insights from pharmacokinetic and pharmacodynamic studies of hydroxychloroquine","volume":"44","author":"Tett","year":"1993","journal-title":"Agents Actions Suppl"},{"key":"2023030220225236900_","first-page":"e00392","article-title":"Systematic analysis of human cells lacking ATG8 proteins uncovers roles for GABARAPs and the CCZ1\/MON1 regulator C18orf8\/RMC1 in macroautophagic and selective autophagic flux","volume":"38","author":"Vaites","year":"2017","journal-title":"Mol Cell Biol"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1016\/j.celrep.2017.06.012","article-title":"The GARP complex is involved in intracellular cholesterol transport via targeting NPC2 to lysosomes","volume":"19","author":"Wei","year":"2017","journal-title":"Cell Rep"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1083\/jcb.103.4.1235","article-title":"Mannose-6-phosphate receptors for lysosomal enzymes cycle between the Golgi complex and endosomes","volume":"103","author":"Brown","year":"1986","journal-title":"J Cell Biol"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"e00149","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: current methodological landscape","volume":"3","author":"Foucquier","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ab.2012.02.033","article-title":"Imaging lysosomal enzyme activity in live cells using self-quenched substrates","volume":"424","author":"Humphries","year":"2012","journal-title":"Anal Biochem"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1158\/1078-0432.CCR-13-3227","article-title":"Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer","volume":"20","author":"Cook","year":"2014","journal-title":"Clin cancer Res"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"18183","DOI":"10.1038\/s41598-021-97434-w","article-title":"Carboplatin response in preclinical models for ovarian cancer: comparison of 2D monolayers, spheroids, ex vivo tumors and in vivo models","volume":"11","author":"Brodeur","year":"2021","journal-title":"Sci Rep"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1515\/hsz-2019-0270","article-title":"Emerging mechanisms of drug-induced phospholipidosis","volume":"401","author":"Breiden","year":"2019","journal-title":"Biol Chem"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ccr.2013.08.003","article-title":"Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase","volume":"24","author":"Petersen","year":"2013","journal-title":"Cancer Cell"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1177\/0192623309348521","article-title":"Phospholipidosis in neurons caused by posaconazole, without evidence for functional neurologic effects","volume":"37","author":"Cartwright","year":"2009","journal-title":"Toxicol Pathol"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1365-2710.2001.00338.x","article-title":"Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics","volume":"26","author":"Willems","year":"2001","journal-title":"J Clin Pharm Ther"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1177\/0961203317727601","article-title":"Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus","volume":"27","author":"Al-Rawi","year":"2018","journal-title":"Lupus"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.bcp.2017.01.010","article-title":"Inhibition of 11\u03b2-hydroxysteroid dehydrogenase 2 by the fungicides itraconazole and posaconazole","volume":"130","author":"Beck","year":"2017","journal-title":"Biochem Pharmacol"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1021\/jm00195a026","article-title":"Lysosomotropic agents. 1. Synthesis and cytotoxic action of lysosomotropic detergents","volume":"22","author":"Firestone","year":"1979","journal-title":"J Med Chem"},{"key":"2023030220225236900_","doi-asserted-by":"crossref","first-page":"5301","DOI":"10.1158\/0008-5472.CAN-04-1427","article-title":"Sensitization to the lysosomal cell death pathway upon immortalization and transformation","volume":"64","author":"Fehrenbacher","year":"2004","journal-title":"Cancer Res"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-22-0037\/3118495\/crc-22-0037.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/5\/293\/3279624\/crc-22-0037.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/5\/293\/3279624\/crc-22-0037.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T10:16:19Z","timestamp":1700475379000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/2\/5\/293\/696275\/Repurposing-Itraconazole-and-Hydroxychloroquine-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,4]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5,4]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-22-0037","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.22544405.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22544411.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22544417","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22544417.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22544408","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22544420","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22544411","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22544414.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22544414","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22544408.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22544405","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22544420.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.6550634.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6550634","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,4]]}}}